Increased sensitivity for better detection

July 13, 2012

A group of European scientists from Imperial College London in the United Kingdom and the University of Vigo in Spain has made a technological breakthrough with its development of an ultra-sensitive test with the capacity to detect signs of a disease in its earliest stages. This study is presented in the journal Nature Materials.

The scientists, including one Marie Curie Action beneficiary, have developed a new diagnostic blood test to detect a called (PSA) that is associated with prostate cancer. Monitoring the levels of PSA at ultra-low concentrations is crucially important for early diagnosis, particularly for those patients with reoccurrence, It should be noted that current detection approaches are not sufficiently sensitive to carry out this analysis with a high degree of accuracy.

"It is vital to detect diseases at an early stage if we want people to have the best possible outcomes - diseases are usually easier to treat at this stage, and early diagnosis can give us the chance to halt a disease before symptoms worsen," said senior author Professor Molly Stevens from the Departments of Materials and Bioengineering at Imperial College London. "However, for many diseases, using current technology to look for early signs of disease can be like finding the proverbial needle in a haystack. Our new test can actually find that needle. We only looked at the biomarker for one disease in this study, but we're confident that the test can be adapted to identify many other diseases at an early stage."

The researchers detected PSA in whole serum at concentrations of nine orders of magnitude lower than tests currently in use. They achieved such ultra-sensitivity with an enzyme called glucose oxidase (GOx), which controls the rate of crystallization of silver to favour either the or growth of on plasmonic nanosensors (gold nanostars) which register the signal. By taking advantage of a so-called "inverse sensitivity phenomenon," the scientists coupled the enzyme to antibodies specific for PSA and used it in immunoassays to detect PSA in the range of 10-18 g/ml.

The team plans to carry out further clinical testing to assess the efficacy of the biosensor in detecting a range of different biomarkers associated with various diseases, such as AIDS. They will also explore ways of commercialising their product.

Explore further: Biomarker panel identifies prostate cancer with 90 percent accuracy

Related Stories

Recommended for you

New method facilitates research on fuel cell catalysts

October 8, 2015

While the cleaning of car exhausts is among the best known applications of catalytic processes, it is only the tip of the iceberg. Practically the entire chemical industry relies on catalytic reactions. Therefore, catalyst ...

Better fluorescent lighting through physics

October 8, 2015

General Electric (GE), Lawrence Livermore National Laboratory (LLNL) and Oak Ridge National Laboratory (ORNL) have created new kinds of fluorescent lighting phosphors that use far less rare-earth elements than current technology.

Porous material holds promise for prosthetics, robots

October 8, 2015

Cornell researchers have developed a new lightweight and stretchable material with the consistency of memory foam that has potential for use in prosthetic body parts, artificial organs and soft robotics. The foam is unique ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.